Yondri N.

Tasidjawa P1505212001 Biomedik-kimia klinik

Monoclonal Antibody
Rabbit Monoclonal Antibodies (RabMAbs) are

developed using a unique and proprietary method for developing monoclonal antibodies from rabbits rather than the conventional method of starting with mice.

Making rabbit monoclonal antibodies

Phase 1 (8-12 minggu Immunsasi 2 kelinci Memantau titer antisera Mengambil darah dan pilih 1 serum kelinci yang positif

Rabbit Monoclonal Antibody Technology

http://www.ivdtechnology.com/sites/www.ivdtechnology.c om/files/image/1305/zhu_table1WEB.jpg

Phase II (5-6 minggu)

Isolasi sel dari serum kelinci yang positif kemudian fusikan dengan 240 E-W cell line Gunakan ELISA untuk screen 40-96 plates fusi ambil 15 supernatan yang positif untuk dites

Phase III (8-10 minggu) Subklon dan

menghasilkan subklon hibdroma

Beberapa keuntungan menggunakan (RabMAbs)

Mengenali bermacam-macam epitop
Meningkatkan respon imun untuk ukuran epitop

yang kecil Memiliki spesifitas dan afinitas yang tinggi Menigkatkan respon terhadap antigen tikus.

RabMAbs comparison with Mouse Monoclonal Antibodies

Perbandingan RabMABs
Sukses yg besar dengan jangkauan antigen termasuk molekulkecil dan peptida Respon yg baik untuk protein hewan pengerat Mengenali beberapa epitop per antigen protein

Mouse Monoclonal
respon imun yg terbatas molekul/peptida kecil sering non immunogenik respon sangat terbatas untuk antigen hewan pengerat Mengenali epitop dalam jumlah yg terbatas

Mengenali antigen

RabMAbs comparison with Mouse Monoclonal Antibodies

Perbandingan RabMABs
Picomolar (1012 KD M) possible

Mouse Monoclonal
Nanomolar (~10-9 KD M)

AFFINITY Spesifitas

tinggi
Western blot, ELISA, Flow Cytometry, IP, IHC, ICC (excellent results in IHC)

Medium-tinggi
Western blot, ELISA, Flow Cytometry, IP, not always suitable for IHC, ICC.

Aplikasi

Perbadingan spesifitas Antibodi kelinci

Perbandingan respon imun

Applications in Diagnostics
Digunakan dalam bentuk reagen untuk fiksasi di lab patologi anatomi

Companion diagnostics
Rab-MAbs have been demonstrated to be superior reagents for detecting subtle protein modifications such as phosphorylation, methylation, acetylation, and glycosylation

Immunoassays for small molecules.

. Immunodiagnostics in body fluids such as blood,

urine, and saliva is the largest IVD segment. Most point-of-care tests belong to this category . From an antigen perspective, immunodiagnostic tests include microbial antigens such as viral, bacterial, fungal, and parasitic antigens; nonmicrobial antigens such as tumor antigens and auto-antigens; and nonclinically relevant antigens such as food toxins or environmental contaminants.

Immunoassays for cancer and cardiac markers

A significant number of cancer antigens are glycoproteins on

tumor cell surfaces such as CA-50, CA-153, CA-199, and CA72-4, and many antibodies actually recognize the carbohydrate epitopes on the glycoproteins instead of protein. Developing more-sensitive or specific antibodies to these carbohydrate epitopes will lead to better or novel diagnoses. In the cardiac disease diagnostic area, more-sensitive and specific antibodies to Troponin I, BNP (B-type natriuretic peptide), and D-dimer are needed for better or early detection of acute coronary syndrome, congestive heart failure, and thrombotic disorders. We believe the new form of antibody, RabMAb technology, will change the diagnostic landscape when more best-in-class antibodies are developed and incorporated into medical devices.

Conclusion
Sistem

imun kelinci menghasilkan bermacammacam antibodi dan mengoptimalkan kemampuan mengikat melalui mekanisme yang lebih efisisen dibandingkan tikus dan hewan pengerat lainnya . Meningkatkan kualitas antibodi untuk aplikasi diagnostik . Dan kemajuan signifikan afinitas dan spesifitas antibodi dipakai dalm diagnosis,prognosis, dan diagnosis berpasangan yang lebih sensitiv,presisi, dan akurat.

Referensi

http://www.ivdtechnology.com www.spinger.com/cda/content www.epitomics.com http://www.abcam.com/RabMAbs W Zhu and G-L Yu, Rabbit Hybridoma, in Therapeutic Monoclonal Antibodies: from bench to clinic, (Wiley, 2009) 151-168 Y Yu et al., A Humanized Anti-VEGF Rabbit Monoclonal Antibody Inhibits Angiogenesis and Blocks Tumor Growth in Xenograft Models,PLoS ONE 5 (2010): 2-12 Jose G et al., Comparison of rabbit monoclonal and mouse monoclonal antibodies in immunohistochemistry in canine tissues. J Vet Diagn Invest 17 (2005) :346